Post by jclint on Jan 4, 2011 15:16:24 GMT -5
Protandim® Found to Prevent a Process that Causes Blood Vessel Blockage in New Peer-Reviewed Study From The Ohio State University
Protandim® prevents the proliferation of cells that can cause re-blockage of vessels following coronary artery bypass surgery, stenting, and carotid enarterectomy
Related Quotes
Symbol Price Change
LFVN.OB 0.41 +0.04
Chart for LIFEVANTAGE CORP
Press Release Source: LifeVantage Corporation On Tuesday January 4, 2011, 8:00 am EST
SAN DIEGO, Jan. 4, 2011 /PRNewswire/ -- LifeVantage Corporation (OTC Bulletin Board:LFVN.ob - News), the maker of science-based solutions to oxidative stress, announced today that a new peer-reviewed study involving its flagship product, Protandim®, sponsored by the American Heart Association and the National Institutes of Health, was published in the scientific journal Free Radical Biology and Medicine.[/color] The study, conducted by researchers at The Ohio State University, examined the biochemical mechanisms that underlie the ability of Protandim® to suppress intimal hyperplasia (over-proliferation of cells that line the vessel wall), a common adverse event that limits the effectiveness of several types of vascular surgery. Protandim®, a patented dietary supplement comprised of five highly synergistic herbal ingredients, has been shown in earlier studies to activate the transcription factor Nrf2, a signal to the cell's DNA to regulate a network of protective genes. This new study further investigates Protandim's® ability to increase production of the body's Nrf2-regulated protective genes, sometimes referred to as "survival genes", which include most of the antioxidant enzymes.
The study, titled "Protandim attenuates intimal hyperplasia in human saphenous veins cultured ex vivo via a catalase-dependent pathway" by Binata Joddar, Rashmeet K. Reen, Michael S. Firstenberg, Saradhadevi Varadharaj, Joe M. McCord, Jay L. Zweier, and Keith J. Gooch is published in the journal Free Radical Biology and Medicine and may be found at the following link.
Coronary artery bypass graft (CABG) surgery is performed more than 400,000 times a year in the United States. Most procedures requiring multiple bypasses still utilize the saphenous vein (taken from the leg) for secondary grafts. Ten years after CABG surgery, roughly half of the saphenous vein grafts will have become largely, if not completely blocked by processes that may result from intimal hyperplasia. Previous studies concluded that a major factor causing this condition is the three-to-five-fold higher concentration of oxygen experienced by the graft in its new environment. In this study, treatment with Protandim® significantly increased antioxidant enzyme activity in veins cultured at high oxygen, while reducing free radical levels, lipid peroxidation, and, importantly, reducing intimal proliferation to the level seen in a normal healthy saphenous vein.
"This study was conducted in an ex vivo model using human saphenous veins harvested from patients undergoing bypass surgery—the exact population who might benefit from a therapy to prevent intimal hyperplasia," said Dr. McCord, a co-author of the study. "Future animal studies will attempt to demonstrate the ability of Protandim® to block post-surgical intimal hyperplasia in vivo, following not only the CABG procedure, but perhaps angioplasty with stent insertion or carotid endarterectomy, as well. The long-term effectiveness of all three procedures is limited by eventual restenosis, a return of blockage often due to intimal hyperplasia. The three procedures together affect more than 1.5 million Americans every year."
"Protandim® was shown in an earlier human trial to increase antioxidant enzyme production and to eliminate the age-dependent increase in the most widely used marker of oxidative stress. The current study, as well as other recent studies, have shown that Protandim® provides benefits to the body that extend beyond its ability to decrease oxidative stress," stated David Brown, LifeVantage President and CEO. "This study was independently funded by the American Heart Association and by the Heart, Lung, Blood Institute of the National Institutes of Health. LifeVantage greatly appreciates the continuing academic interest in Protandim® shown by researchers such as Dr. Keith Gooch and his colleagues. We continue to be encouraged at the tool that Protandim® has become for researchers of many health conditions associated with oxidative stress."
Protandim® prevents the proliferation of cells that can cause re-blockage of vessels following coronary artery bypass surgery, stenting, and carotid enarterectomy
Related Quotes
Symbol Price Change
LFVN.OB 0.41 +0.04
Chart for LIFEVANTAGE CORP
Press Release Source: LifeVantage Corporation On Tuesday January 4, 2011, 8:00 am EST
SAN DIEGO, Jan. 4, 2011 /PRNewswire/ -- LifeVantage Corporation (OTC Bulletin Board:LFVN.ob - News), the maker of science-based solutions to oxidative stress, announced today that a new peer-reviewed study involving its flagship product, Protandim®, sponsored by the American Heart Association and the National Institutes of Health, was published in the scientific journal Free Radical Biology and Medicine.[/color] The study, conducted by researchers at The Ohio State University, examined the biochemical mechanisms that underlie the ability of Protandim® to suppress intimal hyperplasia (over-proliferation of cells that line the vessel wall), a common adverse event that limits the effectiveness of several types of vascular surgery. Protandim®, a patented dietary supplement comprised of five highly synergistic herbal ingredients, has been shown in earlier studies to activate the transcription factor Nrf2, a signal to the cell's DNA to regulate a network of protective genes. This new study further investigates Protandim's® ability to increase production of the body's Nrf2-regulated protective genes, sometimes referred to as "survival genes", which include most of the antioxidant enzymes.
The study, titled "Protandim attenuates intimal hyperplasia in human saphenous veins cultured ex vivo via a catalase-dependent pathway" by Binata Joddar, Rashmeet K. Reen, Michael S. Firstenberg, Saradhadevi Varadharaj, Joe M. McCord, Jay L. Zweier, and Keith J. Gooch is published in the journal Free Radical Biology and Medicine and may be found at the following link.
Coronary artery bypass graft (CABG) surgery is performed more than 400,000 times a year in the United States. Most procedures requiring multiple bypasses still utilize the saphenous vein (taken from the leg) for secondary grafts. Ten years after CABG surgery, roughly half of the saphenous vein grafts will have become largely, if not completely blocked by processes that may result from intimal hyperplasia. Previous studies concluded that a major factor causing this condition is the three-to-five-fold higher concentration of oxygen experienced by the graft in its new environment. In this study, treatment with Protandim® significantly increased antioxidant enzyme activity in veins cultured at high oxygen, while reducing free radical levels, lipid peroxidation, and, importantly, reducing intimal proliferation to the level seen in a normal healthy saphenous vein.
"This study was conducted in an ex vivo model using human saphenous veins harvested from patients undergoing bypass surgery—the exact population who might benefit from a therapy to prevent intimal hyperplasia," said Dr. McCord, a co-author of the study. "Future animal studies will attempt to demonstrate the ability of Protandim® to block post-surgical intimal hyperplasia in vivo, following not only the CABG procedure, but perhaps angioplasty with stent insertion or carotid endarterectomy, as well. The long-term effectiveness of all three procedures is limited by eventual restenosis, a return of blockage often due to intimal hyperplasia. The three procedures together affect more than 1.5 million Americans every year."
"Protandim® was shown in an earlier human trial to increase antioxidant enzyme production and to eliminate the age-dependent increase in the most widely used marker of oxidative stress. The current study, as well as other recent studies, have shown that Protandim® provides benefits to the body that extend beyond its ability to decrease oxidative stress," stated David Brown, LifeVantage President and CEO. "This study was independently funded by the American Heart Association and by the Heart, Lung, Blood Institute of the National Institutes of Health. LifeVantage greatly appreciates the continuing academic interest in Protandim® shown by researchers such as Dr. Keith Gooch and his colleagues. We continue to be encouraged at the tool that Protandim® has become for researchers of many health conditions associated with oxidative stress."